{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:58:15Z","timestamp":1783576695010,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00259-021-05539-1","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T02:47:13Z","timestamp":1632451633000},"page":"1052-1062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Head-to-head comparison of [68\u00a0Ga]Ga-P16-093 and [68\u00a0Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients"],"prefix":"10.1007","volume":"49","author":[{"given":"Guochang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"5539_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccell.2020.06.008","volume":"38","author":"A Paschalis","year":"2020","unstructured":"Paschalis A, de Bono JS. Prostate Cancer 2020: \u201cThe times they are a\u2019changing.\u201d Cancer Cell. 2020;38:25\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.008.","journal-title":"Cancer Cell"},{"key":"5539_CR2","doi-asserted-by":"publisher","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042.","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"5539_CR3","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Han D, Wu P, Ren J, Ma S, Zhang J, et al. Comparison of (68)Ga-PSMA-617 PET\/CT with mpMRI for the detection of PCa in patients with a PSA level of 4\u201320 ng\/ml before the initial biopsy. Sci Rep. 2020;10:10963. https:\/\/doi.org\/10.1038\/s41598-020-67385-9.","journal-title":"Sci Rep"},{"key":"5539_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41391-020-00292-2","volume":"24","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9 BM, Isra\u00ebl B, Schilham MGM, Muselaers CHJ, Z\u00e1mecnik P, Mulders PFA, et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2021;24:423\u201330. https:\/\/doi.org\/10.1038\/s41391-020-00292-2.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5539_CR5","doi-asserted-by":"publisher","unstructured":"Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database System Rev. 2019;4:Cd012663. https:\/\/doi.org\/10.1002\/14651858.CD012663.pub2.","DOI":"10.1002\/14651858.CD012663.pub2"},{"key":"5539_CR6","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"5539_CR7","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256\u201361. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19980601)82:11%3c2256::aid-cncr22%3e3.0.co;2-s.","journal-title":"Cancer"},{"key":"5539_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339. https:\/\/doi.org\/10.1002\/jcb.10661.","journal-title":"J Cell Biochem"},{"key":"5539_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R, Shah RB, Li H, M\u00f6ller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696\u2013701. https:\/\/doi.org\/10.1016\/j.humpath.2006.11.012.","journal-title":"Hum Pathol"},{"key":"5539_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887\u201397. https:\/\/doi.org\/10.1007\/s00259-013-2660-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR11","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","volume":"48","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:2978\u201389. https:\/\/doi.org\/10.1007\/s00259-021-05210-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"5539_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1148\/radiol.2018181981","volume":"289","author":"AC Civelek","year":"2018","unstructured":"Civelek AC. (68)Ga-PSMA-11 PET: better at detecting prostate cancer than multiparametric MRI? Radiology. 2018;289:738\u20139. https:\/\/doi.org\/10.1148\/radiol.2018181981.","journal-title":"Radiology"},{"key":"5539_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","volume":"59","author":"Z Zha","year":"2018","unstructured":"Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF. Synthesis and evaluation of a novel urea-based (68)Ga-complex for imaging PSMA binding in tumor. Nucl Med Biol. 2018;59:36\u201347. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.007.","journal-title":"Nucl Med Biol"},{"key":"5539_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11307-019-01421-7","volume":"22","author":"MA Green","year":"2020","unstructured":"Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, et al. [(68)Ga]Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [(68)Ga]Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence. Mol Imag Biol. 2020;22:752\u201363. https:\/\/doi.org\/10.1007\/s11307-019-01421-7.","journal-title":"Mol Imag Biol"},{"key":"5539_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel, Switzerland). 2014;7:779\u201396. https:\/\/doi.org\/10.3390\/ph7070779.","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"5539_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0883-2897(88)90163-8","volume":"15","author":"CJ Mathias","year":"1988","unstructured":"Mathias CJ, Sun YZ, Welch MJ, Green MA, Thomas JA, Wade KR, et al. Targeting radiopharmaceuticals: comparative biodistribution studies of gallium and indium complexes of multidentate ligands. Int J Rad Appl Instrument Part B Nucl Med Biol. 1988;15:69\u201381. https:\/\/doi.org\/10.1016\/0883-2897(88)90163-8.","journal-title":"Int J Rad Appl Instrument Part B Nucl Med Biol"},{"key":"5539_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/bc00003a005","volume":"1","author":"CJ Mathias","year":"1990","unstructured":"Mathias CJ, Sun YZ, Welch MJ, Connett JM, Philpott GW, Martell AE. N, N\u2032-bis(2-hydroxybenzyl)-1-(4-bromoacetamidobenzyl)-1,2 -ethylenediamine-N, N\u2032-diacetic acid: a new bifunctional chelate for radiolabeling antibodies. Bioconjug Chem. 1990;1:204\u201311. https:\/\/doi.org\/10.1021\/bc00003a005.","journal-title":"Bioconjug Chem"},{"key":"5539_CR19","first-page":"1366","volume":"33","author":"M Zoller","year":"1992","unstructured":"Zoller M, Schuhmacher J, Reed J, Maier-Borst W, Matzku S. Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET. J Nucl Med. 1992;33:1366\u201372.","journal-title":"J Nucl Med"},{"key":"5539_CR20","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1007\/s00259-018-4037-9","volume":"45","author":"C Liu","year":"2018","unstructured":"Liu C, Liu T, Zhang N, Liu Y, Li N, Du P, et al. (68)Ga-PSMA-617 PET\/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2018;45:1852\u201361. https:\/\/doi.org\/10.1007\/s00259-018-4037-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596\u2013604. https:\/\/doi.org\/10.2967\/jnumed.120.257238.","journal-title":"J Nucl Med"},{"key":"5539_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","volume":"49","author":"HJ Wester","year":"2019","unstructured":"Wester HJ, Schottelius M. PSMA-targeted radiopharmaceuticals for imaging and therapy. Semin Nucl Med. 2019;49:302\u201312. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.02.008.","journal-title":"Semin Nucl Med"},{"key":"5539_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395. https:\/\/doi.org\/10.1007\/s00259-012-2298-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697\u2013705. https:\/\/doi.org\/10.2967\/jnumed.115.161299.","journal-title":"J Nucl Med"},{"key":"5539_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914\u201320. https:\/\/doi.org\/10.2967\/jnumed.114.147413.","journal-title":"J Nucl Med"},{"key":"5539_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.115.156133","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855\u201361. https:\/\/doi.org\/10.2967\/jnumed.115.156133.","journal-title":"J Nucl Med"},{"key":"5539_CR27","doi-asserted-by":"publisher","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Comprehen Cancer Netw: JNCCN. 2021;19:134\u201343. https:\/\/doi.org\/10.6004\/jnccn.2021.0008.","DOI":"10.6004\/jnccn.2021.0008"},{"key":"5539_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11\u201320. https:\/\/doi.org\/10.1007\/s00259-013-2525-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185\u201390. https:\/\/doi.org\/10.2967\/jnumed.115.160382.","journal-title":"J Nucl Med"},{"key":"5539_CR30","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(19)30415-2.","journal-title":"Lancet Oncol"},{"key":"5539_CR31","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-20-0587","volume":"26","author":"B Wang","year":"2020","unstructured":"Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A prospective trial of (68)Ga-PSMA and (18)F-FDG PET\/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020;26:4551\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0587.","journal-title":"Clin Cancer Res"},{"key":"5539_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher I, Kr\u00f6nke M, K\u00f6nig M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61:51\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.229187.","journal-title":"J Nucl Med"},{"key":"5539_CR33","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1097\/rlu.0000000000002703","volume":"44","author":"B Pernthaler","year":"2019","unstructured":"Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT. Clin Nucl Med. 2019;44:e566\u201373. https:\/\/doi.org\/10.1097\/rlu.0000000000002703.","journal-title":"Clin Nucl Med"},{"key":"5539_CR34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in (68)Ga- PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44:765\u201375. https:\/\/doi.org\/10.1007\/s00259-016-3578-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00259-019-04569-0","volume":"47","author":"C Sachpekidis","year":"2020","unstructured":"Sachpekidis C, Afshar-Oromieh A, Kopka K, Strauss DS, Pan L, Haberkorn U, et al. (18)F-PSMA-1007 multiparametric, dynamic PET\/CT in biochemical relapse and progression of prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:592\u2013602. https:\/\/doi.org\/10.1007\/s00259-019-04569-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5539_CR36","doi-asserted-by":"publisher","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Molec Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","DOI":"10.1007\/s00259-017-3670-z"},{"key":"5539_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2967\/jnumed.117.195172","volume":"59","author":"N Woythal","year":"2018","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical validation of PSMA expression measured by (68)Ga-PSMA PET\/CT in primary prostate cancer. J Nucl Med. 2018;59:238\u201343. https:\/\/doi.org\/10.2967\/jnumed.117.195172.","journal-title":"J Nucl Med"},{"key":"5539_CR38","doi-asserted-by":"publisher","first-page":"263S","DOI":"10.2967\/jnumed.120.254532","volume":"61","author":"WA Weber","year":"2020","unstructured":"Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, et al. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med. 2020;61:263S-S272. https:\/\/doi.org\/10.2967\/jnumed.120.254532.","journal-title":"J Nucl Med"},{"key":"5539_CR39","doi-asserted-by":"publisher","unstructured":"Sartor O, Hope TA, Calais J, Fendler WP. Oliver Sartor talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler about FDA approval of PSMA. J Nucl Med. 2021;62:146\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.261834.","DOI":"10.2967\/jnumed.120.261834"},{"key":"5539_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2967\/jnumed.120.260455","volume":"62","author":"G Carlucci","year":"2021","unstructured":"Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S. (68)Ga-PSMA-11 NDA approval: a novel and successful academic partnership. J Nucl Med. 2021;62:149\u201355. https:\/\/doi.org\/10.2967\/jnumed.120.260455.","journal-title":"J Nucl Med"},{"key":"5539_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.urolonc.2017.04.014","volume":"35","author":"MH Bagheri","year":"2017","unstructured":"Bagheri MH, Ahlman MA, Lindenberg L, Turkbey B, Lin J, Cahid Civelek A, et al. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urol Oncol. 2017;35:473\u201391. https:\/\/doi.org\/10.1016\/j.urolonc.2017.04.014.","journal-title":"Urol Oncol"},{"key":"5539_CR42","doi-asserted-by":"publisher","unstructured":"Civelek AC, Niglio SA, Malayeri AA, Lin J, Gurram S, Chalfin HJ, et al. Clinical value of (18)FDG PET\/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urologic Oncol. 2021;S1078\u20131439(21)00181\u20132. https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.024.","DOI":"10.1016\/j.urolonc.2021.04.024"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05539-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05539-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05539-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T12:07:29Z","timestamp":1643630849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05539-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5539"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05539-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institute Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and this study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Hank F. Kung is the founder of Five Eleven Pharma, which holds the patent rights for [<sup>68<\/sup>\u00a0Ga]Ga-P16-093 and related technology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}